Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·

Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris

Publication files not online:

Author: Maat, M.P.M. de · Arnold, A.E.R. · Buuren, S. van · Wilson, J.H.P. · Kluft, C.
Institution: Gaubius Instituut TNO
Source:Thrombosis and Haemostasis, 2, 76, 166-170
Identifier: 233461
Keywords: Biology · c reactive protein · fibrin · fibrinogen · ticlopidine · acute phase response · adult · aged · angina pectoris · article · clinical trial · controlled clinical trial · controlled study · crossover procedure · dna polymorphism · double blind procedure · female · fibrinogen blood level · fibrinogen metabolism · human · male · normal human · priority journal · randomized controlled trial · thrombocyte · thrombocyte aggregation · thrombocyte count · Adult · Aged · Angina Pectoris · Antigens · C-Reactive Protein · Case-Control Studies · Cross-Over Studies · Double-Blind Method · Female · Fibrinogen · Humans · Male · Middle Aged · Platelet Aggregation Inhibitors · Reference Values · Ticlopidine


Elevated plasma fibrinogen levels are associated with an increased risk for cardiac events. Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets and it also has been described that ticlopidine can decrease the plasma fibrinogen level in patients with vascular diseases. The mechanism of this decrease has not yet been elucidated and therefore mechanisms that are known to affect fibrinogen levels were studied, viz. the acute phase reaction, total fibrin plus fibrinogen degradation (TDP) levels and the polymorphisms of the fibrinogen β-gene. The fibrinogen lowering effect of ticlopidine was studied in 26 healthy volunteers, selected on genotype of the BclI polymorphism of the fibrinogen β-gene, and in 26 patients with stable angina pectoris in a double blind, randomized cross-over study. Functional plasma fibrinogen levels were measured with the Clauss assay. Fibrinogen antigen, C-reactive protein (CRP) and TDP levels were measured using an enzyme immune assay (EIA). In the healthy volunteers the functional fibrinogen levels had decreased by 0.20 g/l (9%, p = 0.005 using the paired Student t-test) after 4 weeks of 250 mg bid ticlopidine administration, whereas fibrinogen antigen, CRP and TDP levels were not significantly changed. In the stable angina pectoris patients the pre-treatment fibrinogen, CRP and TDP levels were significantly higher than in the volunteer group. After four weeks 250 mg bid ticlopidine administration the functional fibrinogen levels had decreased by 0.38 g/l (11%, p < 0.005), whereas the fibrinogen antigen, CRP and TDP levels were not significantly changed. The levels of functional and antigen fibrinogen, CRP and TDP did not change significantly during the placebo period in the volunteers or the patients. Neither in the volunteers nor in the patients was the effect of ticlopidine on the fibrinogen levels associated with the fibrinogen β-gene polymorphisms. Therefore, the fibrinogen lowering effect of ticlopidine is likely to be a modulation of the functionality of the molecule and unlikely to be modulated by the acute phase reaction, TDP-levels or the fibrinogen β-gene polymorphisms. Chemicals/CAS: Antigens; C-Reactive Protein, 9007-41-4; Fibrinogen, 9001-32-5; Platelet Aggregation Inhibitors; Ticlopidine, 55142-85-3